These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation; 1994 Apr; 89(4):1545-56. PubMed ID: 8149520 [Abstract] [Full Text] [Related]
5. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. TIMI Study Group. N Engl J Med; 1989 Mar 09; 320(10):618-27. PubMed ID: 2563896 [Abstract] [Full Text] [Related]
6. Impact of age on clinical outcome and postlytic management strategies in patients treated with intravenous thrombolytic therapy. Results from the TIMI II Study. TIMI II Investigators. Aguirre FV, McMahon RP, Mueller H, Kleiman NS, Kern MJ, Desvigne-Nickens P, Hamilton WP, Chaitman BR. Circulation; 1994 Jul 09; 90(1):78-86. PubMed ID: 8026055 [Abstract] [Full Text] [Related]
7. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial. Rogers WJ, Baim DS, Gore JM, Brown BG, Roberts R, Williams DO, Chesebro JH, Babb JD, Sheehan FH, Wackers FJ. Circulation; 1990 May 09; 81(5):1457-76. PubMed ID: 2110033 [Abstract] [Full Text] [Related]
10. Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. The TIMI Investigators. Mueller HS, Forman SA, Menegus MA, Cohen LS, Knatterud GL, Braunwald E. J Am Coll Cardiol; 1995 Oct 09; 26(4):900-7. PubMed ID: 7560615 [Abstract] [Full Text] [Related]
16. Determinants of the need for early acute intervention in patients treated conservatively after thrombolytic therapy for acute myocardial infarction. TAMI-5 Study Group. Muller DW, Topol EJ, Ellis SG, Woodlief LH, Sigmon KN, Kereiakes DJ, George BS, Worley SJ, Samaha JK, Phillips H. J Am Coll Cardiol; 1991 Dec 09; 18(7):1594-601. PubMed ID: 1960302 [Abstract] [Full Text] [Related]
17. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis LD, Lambrew CT. Ann Intern Med; 1991 Aug 15; 115(4):256-65. PubMed ID: 1906692 [Abstract] [Full Text] [Related]
18. Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI II. Berger PB, Ruocco NA, Ryan TJ, Frederick MM, Jacobs AK, Faxon DP. J Am Coll Cardiol; 1992 Sep 15; 20(3):533-40. PubMed ID: 1512330 [Abstract] [Full Text] [Related]
19. Impact of treatment strategy on predischarge exercise test in the Thrombolysis in Myocardial Infarction (TIMI) II Trial. Chaitman BR, McMahon RP, Terrin M, Younis LT, Shaw LJ, Weiner DA, Frederick MM, Knatterud GL, Sopko G, Braunwald E. Am J Cardiol; 1993 Jan 15; 71(2):131-8. PubMed ID: 8421972 [Abstract] [Full Text] [Related]